PMID- 33708852
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 9
IP  - 3
DP  - 2021 Feb
TI  - MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal 
      cancer: a cross-sectional analysis of gene status and signal distribution in 
      1,580 patients.
PG  - 225
LID - 10.21037/atm-20-4081 [doi]
LID - 225
AB  - BACKGROUND: MET gene aberrations are found in several human cancers including 
      gastric, ovarian and lung. In a large multinational cohort of patients with 
      gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma we assessed 
      the MET status with respect to amplification and deletion and correlate the 
      results with the phenotypical gene signal distribution pattern. METHODS: Tissue 
      specimens from 1,580 patients were analyzed using a novel fluorescence in situ 
      hybridization (FISH) assay employing a MET/CEN-7 IQFISH Probe Mix. MET 
      amplification and deletions were defined as a MET/CEN-7 ratio >/=2.0 and a 
      MET/CEN-7 ratio <0.8, respectively. Furthermore, the link between the MET gene 
      status and the phenotypical signal distribution was investigated. RESULTS: The 
      prevalence of MET amplification and deletions was found to be 7.2% and 8.7%, 
      respectively. Significant differences were observed with regard to geographic 
      regions and sex. The Asian population had the highest percentage of MET 
      amplification (9.4%) and the lowest percentage of deletions (3.2%). MET deletions 
      was found more frequently among males (10.1%) compared to females (5.3%) and in 
      esophagus (17.6%) compared to the stomach (5.7%). More than 50% of the patients 
      who harbored MET gene amplification had a heterogeneous distribution of the FISH 
      signals. Patients with a focal signal distribution were solely to be found among 
      the MET amplified population. MET deletion were mainly observed in the group of 
      patients with a homogenous signal distribution. CONCLUSIONS: The screening data 
      from this cross-sectional study showed that MET deletion and amplification are 
      frequent events in G/GEJ/E cancer, which are linked to different phenotypical 
      signal distribution patterns. The role of MET deletion in relation to tumor 
      development is not fully understood but it is likely to play a role in the 
      oncogenic transformation of the cells.
CI  - 2021 Annals of Translational Medicine. All rights reserved.
FAU - Jorgensen, Jan Trost
AU  - Jorgensen JT
AD  - Companion Diagnostics, Dx-Rx Institute, Fredensborg, Denmark.
FAU - Mollerup, Jens
AU  - Mollerup J
AD  - Pathology Division, Agilent Technologies, Glostrup, Denmark.
FAU - Yang, Hui
AU  - Yang H
AD  - Medical Sciences, Amgen Inc., Thousand Oaks, USA.
FAU - Go, Ning
AU  - Go N
AD  - Medical Sciences, Amgen Inc., Thousand Oaks, USA.
FAU - Nielsen, Karsten Bork
AU  - Nielsen KB
AD  - Bork Enterprises, Virum, Denmark.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7940901
OTO - NOTNLM
OT  - Mesenchymal epithelial transition factor gene (MET)
OT  - amplification
OT  - deletion
OT  - fluorescence in situ hybridization (FISH)
OT  - gastric cancer
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-4081). JTJ reports other 
      from Employee of Agilent Technologies, personal fees from Agilent Technologies, 
      during the conduct of the study; personal fees from Leo Pharma, personal fees 
      from Alligator Bioscience, personal fees from Agilent Technologies, personal fees 
      from Oncology Venture, personal fees from Azanta, personal fees from Euro 
      Diagnostica, outside the submitted work. He also serves as an unpaid editorial 
      board member of Annals of Translational Medicine from Nov 2016 to Oct 2022. JM 
      reports personal fees from employment by Agilent Technologies, outside the 
      submitted work. The other authors have no conflicts of interest to declare.
EDAT- 2021/03/13 06:00
MHDA- 2021/03/13 06:01
PMCR- 2021/02/01
CRDT- 2021/03/12 07:20
PHST- 2021/03/12 07:20 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/03/13 06:01 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - atm-09-03-225 [pii]
AID - 10.21037/atm-20-4081 [doi]
PST - ppublish
SO  - Ann Transl Med. 2021 Feb;9(3):225. doi: 10.21037/atm-20-4081.